CTLA4 and neoplasm: Similarly, a combination of mTOR kinase inhibitors with immune-checkpoint blockers such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 significantly reduced MC38 or CT-26 tumor development [266].